Early pregnancy soluble E-selectin concentrations and risk of preeclampsia

Objective: Circulating biomarkers of endothelial dysfunction and inflammation are elevated in late pregnancy in women with preeclampsia. We examined plasma levels of inflammatory cytokines and adhesion molecules in early pregnancy, to assess their ability to predict preeclampsia. Methods: In a prospective longitudinal study, 2600 women with singleton pregnancies and no history of hypertension were recruited at their antenatal hospital (booking) visit at gestational week 12–16. Of these, 49 (1.9%) developed preeclampsia, whereas 74 women matched for age and BMI with uncomplicated pregnancies were selected as controls. A subset of women with risk factors for preeclampsia were sampled again at gestational weeks 16 and 28 (11 cases, 39 controls) and postnatally (six cases, 36 controls). Results: From multiplex analysis, soluble E-selectin concentrations were higher at 12–16 weeks in women who subsequently developed preeclampsia (15.1 ± 4.9 versus 12.9 ± 4.5 ng/ml, P = 0.02). At gestational week 28, E-selectin concentrations were again higher in women who went on to develop preeclampsia compared with controls (14.4 ± 5.6 versus 10.7 ± 3.5 ng/ml, P = 0.010), whereas levels were not different between the two groups in postpartum samples. Conclusion: Changes in soluble E-selectin concentration in early pregnancy may reflect underlying pathophysiological processes, potentially providing mechanistic insights into preeclampsia.

[1]  Michael A Black,et al.  Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort , 2011, BMJ : British Medical Journal.

[2]  L. Poston,et al.  Urinary Proteomics for Prediction of Preeclampsia , 2011, Hypertension.

[3]  N. Vitoratos,et al.  Antepartum and postpartum maternal plasma levels of E-selectin in pre-eclampsia, gestational proteinuria and gestational hypertension. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[4]  Zhao-su Wu,et al.  E-selectin gene polymorphisms are associated with essential hypertension: a case-control pilot study in a Chinese population , 2010, BMC Medical Genetics.

[5]  A. Hingorani,et al.  Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function Before and After Preeclampsia and Gestational Hypertension , 2010, Circulation.

[6]  Miin Roh,et al.  Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[7]  M. Aral,et al.  Association of Maternal Serum CRP, IL-6, TNF-α, Homocysteine, Folic Acid and Vitamin B12 Levels with the Severity of Preeclampsia and Fetal Birth Weight , 2009, Hypertension in pregnancy.

[8]  N. Bersinger,et al.  First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. , 2008, American journal of obstetrics and gynecology.

[9]  V. Vital-reyes,et al.  Adhesion molecules changes at 20 gestation weeks in pregnancies complicated by preeclampsia. , 2008, European journal of obstetrics, gynecology, and reproductive biology.

[10]  S. Karumanchi,et al.  Endothelial Dysfunction: A Link Among Preeclampsia, Recurrent Pregnancy Loss, and Future Cardiovascular Events? , 2007, Hypertension.

[11]  I. Sargent,et al.  Inflammation and pre-eclampsia. , 2006, Seminars in fetal & neonatal medicine.

[12]  N. Dzimiri,et al.  E-selectin S128R polymorphism and severe coronary artery disease in Arabs , 2006, BMC Medical Genetics.

[13]  I. Sargent,et al.  Latest Advances in Understanding Preeclampsia , 2005, Science.

[14]  Kirsten Duckitt,et al.  Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies , 2005, BMJ : British Medical Journal.

[15]  L. Cherry,et al.  Short- and Long-Term Changes in Plasma Inflammatory Markers Associated With Preeclampsia , 2004, Hypertension.

[16]  So-Yeon Park,et al.  Maternal Serum Levels of VCAM-1, ICAM-1 and E-selectin in Preeclampsia , 2004, Journal of Korean medical science.

[17]  H. Schlebusch,et al.  Adhesion molecules, activin and inhibin—candidates for the biochemical prediction of hypertensive diseases in pregnancy? , 2004, Archives of Gynecology and Obstetrics.

[18]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[19]  H. Ochi,et al.  Changes in serum concentrations of tumor necrosis factor α and adhesion molecules in normal pregnant women and those with pregnancy‐induced hypertension , 2003, The journal of obstetrics and gynaecology research.

[20]  G. Lip,et al.  Soluble E-selectin in cardiovascular disease and its risk factors , 2003, Thrombosis and Haemostasis.

[21]  M. Sakai,et al.  Th1/Th2 balance in preeclampsia. , 2003, Journal of reproductive immunology.

[22]  Y. Taketani,et al.  Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  K. Kalache,et al.  Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia , 2002, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[24]  V. Bini,et al.  Soluble adhesion molecules: marker of pre-eclampsia and intrauterine growth restriction , 2002, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[25]  A. Blann,et al.  Maternal endothelial soluble cell adhesion molecules with isolated small for gestational age fetuses: comparison with pre‐eclampsia , 2001, BJOG : an international journal of obstetrics and gynaecology.

[26]  C. O'Herlihy,et al.  Plasma P‐selectin is elevated in the first trimester in women who subsequently develop pre‐eclampsia , 2001, BJOG : an international journal of obstetrics and gynaecology.

[27]  Jm Roberts,et al.  Pathogenesis and genetics of pre-eclampsia , 2001, The Lancet.

[28]  Jean-Marie Moutquin,et al.  The Classification and Diagnosis of the Hypertensive Disorders of Pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP) , 2001, Hypertension in pregnancy.

[29]  S. Djurovic,et al.  Altered circulating levels of adhesion molecules at 18 weeks' gestation among women with eventual preeclampsia: indicators of disturbed placentation in absence of evidence of endothelial dysfunction? , 2000, American journal of obstetrics and gynecology.

[30]  K. Conrad,et al.  Circulating Levels of Immunoreactive Cytokines in Women with Preeclampsia , 1998, American journal of reproductive immunology.

[31]  H. Augustin,et al.  Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia. , 1997, American journal of obstetrics and gynecology.

[32]  S. Nussey,et al.  The cell adhesion molecule, VCAM‐1, is selectively elevated in serum in pre‐eclampsia: does this indicate the mechanism of leucocyte activation? , 1995, British journal of obstetrics and gynaecology.

[33]  J. Walker.  Inflammation and preeclampsia. , 2011, Pregnancy hypertension.

[34]  M. Lindheimer,et al.  Maternal infection and risk of preeclampsia: systematic review and metaanalysis. , 2008, American journal of obstetrics and gynecology.